YIM Agenda staging -8-27-21
Monday 13 September 2021
| 8:00 AM (EDT) 14:00 (CEST) |
10 mins | Welcome and Introductions | Welcome & Opening Remarks by Tadeusz Robak, MD, PhD; Petra Langerbeins, MD; Bartosz Pula. MD, PhD |
| 8:10 AM (EDT) 14:10 (CEST) |
Session 1: Pathogenesis of CLL | Chairs: Dimitar Efremov, MD, PhD; Marek Mraz, PhD; & Elisa ten Hacken, PhD | |
| 8:10 AM (EDT) 14:10 (CEST) |
10 mins | Small Extracellular Vesicles Derived from CLL Microenvironment Sustain Disease Progression padding-right: 30px;in Vivo by Hampering Anti-tumor Immunity (1084065) |
Ernesto Gargiulo, MSc |
| 8:20 AM (EDT) 14:20 (CEST) |
10 mins | GAB1 – Novel Regulator of Migration Capacity and Tonic AKT Activity in CLL: Implications for Combinatorial Therapy with BCR Inhibitors (1084081) |
Vaclav Seda, MSc |
| 8:30 AM (EDT) 14:30 (CEST) |
10 mins | Effects of SF3B1 K700E mutation in chronic lymphocytic leukemia and the opportunity for targeted therapy with SF3B1-binding splicing modulator H3B-8800 (1084295) |
Irene Lopez-Oreja, PhD |
| 8:40 AM (EDT) 14:40 (CEST) |
10 mins | Role of Ahr and Hif1a in the Suppressive Ability of Tregs During CLL Development (1083804) |
Giulia Maria Pagano, MSc |
| 8:50 AM (EDT) 14:50 (CEST) |
10 mins | RPS15 mutation impacts B cell fate and drives B cell malignancy through Myc activation in a murine model (1084599) |
Catherine Gutierrez, PhD |
| 9:00 AM (EDT) 15:00 (CEST) |
20 mins |
Recap, Q&A |
|
| 9:20 AM (EDT) 15:20 (CEST) |
5 mins | Break | |
| 9:25 AM (EDT) 15:25 (CEST) |
Session 2: Approach Considerations and Treatment Options in CLL | Chairs: Inhye Ahn, MD; Anthony Mato, MD, MSCE; & Talha Munir, MD |
|
| 9:25 AM (EDT) 15:25 (CEST) |
10 mins | Cell-free DNA (cfDNA)-based Serial Minimal Residual Disease Assessment in Patients with Chronic Lymphocytic Leukemia Treated with Time-limited Obinutuzumab, Acalabrutinib and Venetoclax (1084129) |
Moritz Fürstenau, MD |
| 9:35 AM (EDT) 15:35 (CEST) |
10 mins | Comparison of Clinical and Laboratory Features, Drug Availability, and Outcomes of CLL Patients Treated in Public or in Private Hospitals in Brazil: A Retrospective Analysis of the Brazilian Registry of CLL (1083568) |
Verena Pfister |
| 9:45 AM (EDT) 15:45 (CEST) |
10 mins | VENETOCLAX Ramp-Up Strategies For CLL. UK Real World Multicentre Retrospective Study (1084425) |
Rocío Figueroa |
| 9:55 AM (EDT) 15:55 (CEST) |
10 mins | Utilizing Clinical Features of Progression to Predict Richter’s Syndrome in Patients with CLL Progressing After Ibrutinib (1084068) |
Adam S. Kittai, MD |
| 10:05 AM (EDT) 16:05 (CEST) |
10 mins | Evaluation of Immunoglobulin Gene Somatic Hypermutation Status by Next Generation Sequencing Is Superior to Using Sanger Sequencing (1084095) |
Mengge Gao, MD |
| 10:15 AM (EDT) 16:15 (CEST) |
20 mins |
Recap, Q&A |
|
| 10:35 AM (EDT) 16:35 (CEST) |
5 mins | Break | |
| 10:40 AM (EDT) 16:40 (CEST) |
Session 3: Rationally Designed Therapy on the Horizon in CLL | Chairs: Florence Cymbalista, MD, PhD; Petra Langerbeins, MD; & Bartosz Pula, MD | |
| 10:40 AM (EDT) 16:40 (CEST) |
10 mins | Venetoclax resistance mechanisms in CLL identified by whole exome and RNA sequencing on longitudinal patient samples (1084402) |
Ishwarya Murali |
| 10:50 AM (EDT) 16:50 (CEST) |
10 mins | CD19 promoter hypermethylation as means of antigen-negative escape to CART-19 therapy (1084273) |
Lenka Dostalova |
| 11:00 AM (EDT) 17:00 (CEST) |
10 mins | A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL) (1082565) |
Pallawi Torka, MD |
| 11:10 AM (EDT) 17:10 (CEST) |
10 mins | BTK inhibitors, irrespective of ITK inhibition, downregulate an immunosuppressive program in chronic lymphocytic leukemia and enhance CD19/CD3-mediated cytotoxicity of T cells (1084197) |
Maissa Mhibik, PhD |
| 11:10 AM (EDT) 17:10 (CEST) |
10 mins | Longitudinal antibody Levels and T- cell Response Following BNT162b mRNA Covid19 Vaccine in Patients with Chronic Lymphocytic Leukemia on Behalf of the Israeli CLL Study Group (1083588) |
Tamar Tadmor, MD |
| 11:20 AM (EDT) 17:20 (CEST) |
20 mins |
Recap, Q&A |
|
| 11:30 AM (EDT) 17:30 (CEST) |
10 mins | Break | |
| Concurrent Bootcamp Sessions | |||
| Basic Biology Investigator Bootcamp Poster Presentations From the Podium and Roundtable Discussion (7 min presentation; 3 min discussion) |
Chairs: Shih-Shih Chen, PhD; Davide Rossi, MD, PhD; Freda Stevenson & Elisa TenHacken, PhD | ||
| 12:00 PM (EDT) 18:00 (CEST) |
50 mins | Establishment and Molecular Characterization of a 3D Bioprinted Chronic Lymphocytic Leukemia (CLL) in Vitro Model (1083882) |
Riccardo Pinos, MSc |
| Ibrutinib Blocks CD40 Signaling in CLL in Vivo by Reducing TRAF4 Levels (1084082) |
Sonali Sharma, PhD | ||
| Single-cell RNA Sequencing Suggests Novel Drivers of Chronic Lymphocytic Leukemia in Patients with Ibrutinib Resistance (1084066) |
Hui Jin, MD | ||
| Ebi3/IL-27 Depleted Microenvironment Favours Tumour Progression in Chronic Lymphocytic Leukaemia (1082745) |
Iria Carmen Fernandez Botana, MSc | ||
| Unraveling Functional Consequences of AID Off-target Mutations in CLL (1083548) |
Amparo Rico | ||
| 12:50 PM (EDT) 18:50 (CEST) |
20 mins | Career Development Discussion | Davide Rossi, Freda Stevenson |
| 1:10 PM (EDT) 19:10 (CEST) |
5 mins | Break | |
| Translational Investigator Bootcamp (Poster Presentations From the Podium and Roundtable Discussion (7 min presentation; 3 min discussion) |
Chairs: Chaja Jacobs, MD; Arnon Kater, MD, PhD; & Adrian Wiestner, MD, PhD |
||
| 12:00 PM (EDT) 18:00 (CEST) |
50 mins | Inhibition of the Pentose-phosphate-pathway (PPP) Mediates Macrophage Reprogramming and Induces Increased Antibody-dependent Lymphoma Cell Clearance by Macrophages While Supportive Bystander Function Is Diminished (1084060) |
Anna Beielstein |
| Single-cell Dynamics of Mitochondrial DNA Mutations and Chromatin Accessibility in Chronic Lymphocytic Leukemia Following Therapeutic Bottlenecks (1084075) |
Livius Penter, MD | ||
| IL4-STAT6 Signaling Induces CD20 in Chronic Lymphocytic Leukemia and This Axis Is Repressed by PI3K Inhibitor Idelalisib (1084080) |
Veronika Palusova, PhD | ||
| Pharmacologic Inhibition of SUMO-activating Enzyme Potentiates Interferon Response and T Cell-mediated Anti-tumor Immunity in Chronic Lymphocytic Leukemia (CLL) and Lymphoma Models (1083519) |
Vi Lam, BS | ||
| Targeting Translation by Disrupting the Newly Identified Prohibitin-eIF4F Complex as a Novel Therapeutic Strategy in CLL (1084070) |
Anne Largeot, PhD | ||
| 12:50 PM (EDT) 18:50 (CEST) |
20 mins | Career Development Discussion | |
| 1:10 PM (EDT) 19:10 (CEST) |
5 mins | Break | |
| Clinical Investigator Bootcamp (Poster Presentations From the Podium and Roundtable Discussion (7 min presentation; 3 min discussion) |
Chairs: Matthew Davids, MD, MMSc; Talha Munir, MD; & Jennifer Woyach, MD |
||
| 12:00 PM (EDT) 18:00 (CEST) |
50 mins | Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Sequentially Resistant to Both BCL2 and BTK Inhibition (1083790) |
Victor S. Lin, MD |
| BCL3 Gene Rearrangement at IgH Locus, t(14;19), Identifies an Aggressive Subset of Chronic Lymphocytic Leukemia. an ERIC and Italian Campus CLL Study (1083625) |
Panagiotis Baliakas, MD PhD | ||
| Treatment in the First 24 Months from Diagnosis Predicts Shorter Survival in Binet a Stage Patients with Chronic Lymphocytic Leukemia. a CLL Campus Study (1083334) |
Gianluigi Reda, MD | ||
| Optical Genome Mapping: a new promising tool to assess genomic complexity in chronic lymphocytic leukemia (CLL) (1084272) |
Anna Puiggros, PhD | ||
| Healthcare Team Burden Due To the Utilization of Novel Therapeutics for Chronic Lymphocytic Leukemia (CLL) and Lymphoid Malignancies (1084593) |
Maishara Muquith, B.A. | ||
| 12:50 PM (EDT) 18:50 (CEST) |
20 mins | Career Development Discussion |
Matthew Davids, MD, Talha Munir, MD; & Jennifer Woyach, MD |
| 1:10 PM (EDT) 19:10 (CEST) |
5 mins | Break | |
| Bootcamp Recap and YIM Award Presentation | |||
| 1:15 PM (EDT) 19:15 (CEST) |
30 mins | Recap of Previous Bootcamp Sessions |
TBD |
| 1:45 PM (EDT) 19:45 (CEST) |
15 mins | YIM Award and Concluding Remarks |
Awards – Petra Langerbeins, MD; Bartosz Pula, MD, PhD Concluding Remarks – Tadeusz Robak, MD, PhD |
| 2:00 PM (EDT) 20:00 (CEST) |
Adjourn |